PEGylated liposomes as an emerging therapeutic platform for oral nanomedicine in cancer therapy: in vitro and in vivo assessment

Singh, Archu; Neupane, Yub Raj; Shafi, Sadat; Mangla, Bharti; Kohli, Kanchan

doi:10.1016/j.molliq.2020.112649

Cited by 60 publications

(23 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ex vivo gut permeation study of BBR and BNP formulations was performed using a non-everted rat gut sac model [18,19]. The protocol for the gut permeation experiments was approved by the Institutional Animal Ethical Care Committee (IAEC) of Jamia Hamdard, India (173/CPCSEA/2012).…”

Section: Ex Vivo Gut-permeation Studymentioning

confidence: 99%

“…The in vivo performance of the BBR suspension and BNPs was assessed for their pharmacokinetic performance for further verification of the above experiments and proof of concept. Pharmacokinetic analysis was carried out using the non-compartmental (modelindependent) method [18,19]. Figure 7 shows the plasma concentration-time profiles of BBR from BBR suspension and BNPs after oral administration, while Table 5 shows the various pharmacokinetic parameters.…”

Section: Pharmacokinetic Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Development of Natural Polysaccharide–Based Nanoparticles of Berberine to Enhance Oral Bioavailability: Formulation, Optimization, Ex Vivo, and In Vivo Assessment

et al. 2021

Self Cite

View full text Add to dashboard Cite

The phytogenous alkaloid berberine (BBR) has become a potential drug for the treatment of diabetes, hyperlipidemia, and cancer. However, its therapeutic potential is limited because ofpoor intestinal absorption due to its efflux by the P-gp expressed in the intestinal lumen. Therefore, we aimed to design and fabricate a nanoparticulate system for delivery of BBR employing naturally derived biodegradable and biocompatible polymers, mainly chitosan and alginate, to enhance the oral bioavailability of BBR. A chitosan-alginate nanoparticle system loaded with BBR (BNPs) was formulated by ionic gelation method and was optimized by employing a three-factor, three-level Box-Behnken statistical design. BNPs were characterized for various physicochemical properties, ex vivo, and in vivo evaluations. The optimized BNPs were found to be 202.2 ± 4.9 nm in size, with 0.236 ± 0.02 of polydispersity index, zeta potential −14.8 ± 1.1 mV, and entrapment efficiency of 85.69 ± 2.6%. BNPs showed amorphous nature with no prominent peak in differential scanning calorimetry (DSC) investigation. Similarly, fourier-transform infrared spectroscopy (FTIR) studies did not reveal any interaction between BBR and excipients used. The drug release followed Higuchi kinetics, since these plots demonstrated the highest linearity (R2 = 0.9636), and the mechanism of release was determined to be anomalous or non-Fickian in nature. An ex-vivo gut permeation study showed that BNPs were better internalized into the cells and more highly permeated through the intestine. Furthermore, in vivo pharmacokinetic analysis in female Wistar rats showed a 4.10−fold increase in the oral bioavailability of BBR from BNPs as compared to BBR suspension. With these findings, we have gained new insight into the effective delivery of poorly soluble and permeable drugs via a chitosan-alginate nanoparticle system to improve the therapeutic performance of an oral nanomedicine.

show abstract

Section: Ex Vivo Gut-permeation Studymentioning

confidence: 99%

Section: Pharmacokinetic Studiesmentioning

confidence: 99%

Development of Natural Polysaccharide–Based Nanoparticles of Berberine to Enhance Oral Bioavailability: Formulation, Optimization, Ex Vivo, and In Vivo Assessment

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, Singh et al studied the stability of PEGylated liposomes vs. conventional liposomes after 2 hours of exposure to the harsh conditions of the gastrointestinal environment. They compared the release of the drug from those 2 formulations and observed that if the drug remained in PEGylated liposomes after 2 hours, the drug was totally released with conventional liposomes [23]. For polymeric NP, Tobio et al have also demonstrated that a PEG coating of poly (lactic acid) (PLA) NP increases protection against digestive fluids.…”

Section: Gastrointestinal Stability Of Np In Relation To Their Pk Profilementioning

confidence: 99%

“…Regular PK models used to describe distribution are only considering the active ingredient as a free drug. Some nanomedicines PK models have been published but with the hypothesis that only one type of nanoparticle was administered [23], [39]. However, it is now well known that other species such as micelles can also be present in the formulation besides NP.…”

Section: Characterization Of Np Before Administrationmentioning

confidence: 99%

“…Singh et al have performed an in vivo PK study on liposomes loaded with exemestane (Figure 1), in which they only measure drug concentration without evaluating the integrity of liposomes [23] as well as in the study of Menzel et al with exenatide loaded in a self-emulsifying drug delivered system [39]. Most of the published studies rely on the monitoring of drug bloodconcentration along time, which is relevant for non-encapsulated drugs but is not accurate for nanomedicines as stated before.…”

Section: Characterization Of Np After Administrationmentioning

confidence: 99%

See 1 more Smart Citation

Specificity of pharmacokinetic modeling of nanomedicines

Lebreton

Legeay

Saulnier

et al. 2021

Drug Discovery Today

View full text Add to dashboard Cite

show abstract

Nanomaterial Strategies for Delivery of Therapeutic Cargoes

Ledesma

Ozcan

Sun

et al. 2021

Adv Funct Materials

View full text Add to dashboard Cite

Over the last decade, much progress has been made in developing nanoparticle-mediated delivery systems to overcome the limitations of existing in vivo delivery technologies. However, the balance between efficacy and safety continues to limit the clinical translation of nanoscale delivery systems. Furthermore, optimizing delivery efficiency requires tuning nanoparticle type and attachment chemistry, both of which are dependent on the cargo being delivered. While the delivery of protein therapeutics is of particular interest, the complexity inherent to protein cargo introduces additional challenges for cargo loading and stabilization. Advances needed for efficient and safe in vivo nanoparticle delivery systems should prioritize design strategies that co-optimize safety, biodegradability, and covalent functionalization. In this review, the most commonly used non-viral nanoparticles are outlined for delivery of small molecule drug, nucleic acid, and protein therapeutic cargoes and potential strategies are discussed for rationally designing nanoparticle-mediated delivery systems.

show abstract

PEGylated liposomes as an emerging therapeutic platform for oral nanomedicine in cancer therapy: in vitro and in vivo assessment

Cited by 60 publications

References 69 publications

Development of Natural Polysaccharide–Based Nanoparticles of Berberine to Enhance Oral Bioavailability: Formulation, Optimization, Ex Vivo, and In Vivo Assessment

Development of Natural Polysaccharide–Based Nanoparticles of Berberine to Enhance Oral Bioavailability: Formulation, Optimization, Ex Vivo, and In Vivo Assessment

Specificity of pharmacokinetic modeling of nanomedicines

Nanomaterial Strategies for Delivery of Therapeutic Cargoes

Contact Info

Product

Resources

About